Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Stem Cells are a Soft Touch for Nano-engineered Biomaterials

Published: Wednesday, June 11, 2014
Last Updated: Wednesday, June 11, 2014
Bookmark and Share
Scientists from Queen Mary University of London have shown that stem cell behaviour can be modified by manipulating the nanoscale properties of the material they are grown on - improving the potential of regenerative medicine and tissue engineering as a result.

Stem cells are special because they are essential to the normal function of our organs and tissues. Previous research shows stem cells grown on hard substrates go on to multiply but do not differentiate: a process by which the cells specialize to perform specific functions in the body. In contrast, stem cells grown on softer surfaces do go on to differentiate.

In this new study, published in the journal Nano Letters, the researchers used tiny material patches known as nanopatches to alter the surface of the substrate and mimic the properties of a softer material.

“By changing the surface properties like the shape of the substrate at the nanoscale level, we tricked the stem cells to behave differently,” explains co-author Dr Julien Gautrot, from QMUL’s School of Engineering and Materials Science and the Institute of Bioengineering.

The team tested different sizes of the nanopatches - from 3 microns to 100 nanometres (about one thousandth of the diameter of a hair). The stem cells behaved as if they were on a soft surface when in contact with the smallest patches because they can’t firmly grip them.

Dr Gautrot added: “This development will be useful when there’s a need to create a rigid implant to be inserted into the body. Potentially, such nanopatches could provide a soft touch to the surface of the implant so that cells from the neighbouring tissues are not perturbed by such a hard material.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Nanosensors Could Determine Tumours’ Ability to Remodel Tissue
Researchers design nanosensors that can profile tumours, focusing on protease levels.
1960s Antibiotics Show Promise for TB Therapy
Research suggests antibiotics introduced in 1963 to treat bacterial infections show promise for tuberculosis therapy.
Insight into Eye Diseases
Scientists recreate zebrafish cell regeneration from retinal stem cells in mice.
Analysing 10,000 Cells Simultaneously
New techniquethat traps 10,000 cells on a single chip has potential for cancer screening for individuals.
Studies Explore the Science of Cardiovascular Diseases
Two studies highlight how basic science research insights are key to future treatment breakthroughs.
Stem Cell ‘Heart Patch’ Almost Perfected
Scientists aiming to perfect and test 3D "heart patches" in animal model, last hurdle before human patients.
Using Stem Cells to Grow a 3D Lung-in-a-Dish
Researchers have created 3D lung-like tissue from lung-derived stem cells. The tissue can be used to study lung diseases.
MRI Guidance Aids Stem Cell Delivery
Scientists have delivered stem cells to the brain with unprecedented precision, infusing the cells under real-time MRI guidance.
Mechanisms of Parkinson’s Pathology
Defects that lead to cells’ failure to decommission faulty mitochondria cause nerve cells to die, triggering the symptoms of Parkinson’s disease.
Advanced Lymphoma in Remission After T-Cell Therapy
63% of trial participants who recieved two-drug combination chemo plus intermediate dose of engineered T cells went into complete remission.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!